Creating new PET imaging tools for diagnosing brain diseases.
Development of Emergent PET Tracers in Frontotemporal Lobar Degeneration
['FUNDING_OTHER'] · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · NIH-11088861
This study is working on new imaging tools to help doctors better diagnose and track neurodegenerative diseases like Alzheimer's, so patients can get more accurate information and better treatment options.
Quick facts
| Phase | ['FUNDING_OTHER'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | UNIVERSITY OF CALIFORNIA, SAN FRANCISCO (nih funded) |
| Locations | 1 site (SAN FRANCISCO, UNITED STATES) |
| Trial ID | NIH-11088861 on ClinicalTrials.gov |
What this research studies
This research focuses on developing innovative PET tracers that can help diagnose and monitor neurodegenerative diseases, particularly those related to frontotemporal lobar degeneration (FTLD). The project is led by Dr. David Soleimani-Meigooni at the UCSF Memory and Aging Center, where he aims to enhance his skills in imaging techniques and quantitative analysis. By utilizing advanced imaging methods, the research seeks to improve the accuracy of diagnosing conditions like Alzheimer's disease and related disorders. Patients may benefit from more precise diagnostic tools that can lead to better treatment plans.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals experiencing symptoms of neurodegenerative diseases, particularly those with frontotemporal lobar degeneration or Alzheimer's disease.
Not a fit: Patients with non-neurodegenerative conditions or those who do not exhibit symptoms related to cognitive decline may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could provide patients with more accurate and earlier diagnoses of neurodegenerative diseases, leading to improved management and treatment options.
How similar studies have performed: Previous research has shown promise in developing PET tracers for neurodegenerative diseases, indicating that this approach has potential for success.
Where this research is happening
SAN FRANCISCO, UNITED STATES
- UNIVERSITY OF CALIFORNIA, SAN FRANCISCO — SAN FRANCISCO, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: SOLEIMANI-MEIGOONI, DAVID NIMA — UNIVERSITY OF CALIFORNIA, SAN FRANCISCO
- Study coordinator: SOLEIMANI-MEIGOONI, DAVID NIMA
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions: Alzheimer disease dementia, Alzheimer syndrome, Alzheimer's Disease, Alzheimer's disease patient